Vaccine treatment for children with low-grade gliomas

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety, immunogenicity, and preliminary efficacy of a glioma-associated antigen peptide vaccine combined with poly-ICLC in children with unresectable low-grade gliomas who have undergone at least two prior chemotherapy or biologic treatments. Participants will receive subcutaneous injections of the vaccine every three weeks for up to eight cycles, alongside intramuscular administration of poly-ICLC. The study will monitor patients for adverse events and clinical responses through regular MRI scans and clinical visits.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Tumor Type

* Unresectable low-grade gliomas that have received at least two chemotherapy/biologic regimens. Radiation therapy counts as a biologic regimen. Patients may not have received radiation therapy to the index lesion within 1 year of enrollment. Patients may have tumor spread within the central nervous system (CNS).
* HLA-A2 positive based on flow cytometry.
* Patients must be clinically stable and off or on low-dose (no more than 0.1 mg/kg/day, max 4 mg/day Dexamethasone) corticosteroid for at least one week prior to study registration.
* Patients must be ≥ 12 months and \< 22 years of age at the time of HLA-A2 screening.
* Patients must have a performance status of ≥ 70; (Karnofsky if \> 16 years and Lansky if ≤ 16 years of age.
* Documented negative serum beta-human chorionic gonadotropin (HCG) for female patients who are post-menarchal. Because the effect of the peptide-based vaccine and poly-ICLC on the fetus has not sufficiently been investigated, pregnant females will not be included in the study.
* Patients must be free of systemic infection requiring IV antibiotics at the time of registration. Patients must be off IV antibiotics for at least 7 days prior to registration.
* Patients with adequate organ function as measured by: Bone marrow: absolute neutrophil count (ANC) \> 1,000/µ; Platelets \> 100,000/µ (transfusion independent); absolute lymphocyte count of ≥ 500/µ; Hemoglobin \>8 g/dl (may be transfused). Hepatic: bilirubin \< 1.5x institutional normal for age; serum glutamate pyruvate transaminase (SGPT) \< 3x institutional normal.
* Renal: Serum creatinine based on age or Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 70 ml/min/ml/min/1.73 m²
* Patients must have recovered from the toxic effects of prior therapy to grade 1 or better. Patients must be at least 3 weeks from the last dose of standard cytotoxic chemotherapy or myelosuppressive biological therapy and at least 1 week from the last dose of non-myelosuppressive biologic therapy.
* No overt cardiac, gastrointestinal, pulmonary or psychiatric disease.

Exclusion Criteria:

* Patients living outside of North America are not eligible.
* Patients may not have received radiation to the index lesion within 1 year of enrollment.
* Concurrent treatment or medications (must be off for at least 1 week) including:

  * Interferon (e.g. Intron-A®)
  * Allergy desensitization injections
  * Growth factors (e.g. Procrit®, Aranesp®, Neulasta®)
  * Interleukins (e.g. Proleukin®)
  * Any investigational therapeutic medication
* Patients must not have a history of, or currently active autoimmune disorders requiring cytotoxic or immunosuppressive therapy, or autoimmune disorders with visceral involvement.
* Use of immunosuppressives within four weeks prior to study entry or anticipated use of immunosuppressive agents. Dexamethasone, or other corticosteroid medications, if used in the peri-operative period must be tapered to no more than 0.1 mg/kg/day, max 4 mg/day dexamethasone for at least one week before study registration. Topical corticosteroids are acceptable.
* Because patients with immune deficiency are not expected to respond to this therapy, HIV-positive patients are excluded from the study.
* Patients who have received prior immunotherapy.

Where it's running

• Children's Hospital of Pittsburgh of UPMC
  Pittsburgh, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: James Felker, MD — University of Pittsburgh
• Study coordinator: James Felker, MD
• Phone: 412 692-5055

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Low-grade gliomas in Argentina: Incidence, survival, and treatment patterns

  This study tests how common low-grade gliomas are in Argentina and how long patients live after diagnosis, using two groups from Buenos Aires and Córdoba.

  Recruiting at 6 sites Hospital Italiano de Buenos Aires · Buenos Aires, Buenos Aires F.D. and 5 other locations · NCT07631338

• Laser thermal therapy for young people with low-grade glioma

  This research will test whether laser interstitial thermal therapy (LITT) can stop or slow recurrent or progressive low-grade gliomas in children, adolescents, and young adults.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07506239

• Dabrafenib and trametinib dose-reduction for BRAF V600 low-grade glioma

  This trial tries to see if stopping or slowly lowering dabrafenib and trametinib after about 12–24 months works for people with BRAF V600–mutant low-grade glioma.

  Recruiting at 12 sites Phase 2 University of California, San Francisco · Birmingham, Alabama and 11 other locations · NCT07110246

• Home-based self-management and cognitive training for brain tumor survivors

  This trial will try a home-based cognitive coaching program to see if it improves thinking and quality of life for adults who survived non-glioblastoma brain tumors, with optional caregiver participation.

  Recruiting Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire · NCT06930846

• Combining MAPK inhibitors with anti-PD1 therapy for pediatric gliomas with BRAF alterations

  This study is testing if combining two cancer drugs with a new therapy can help children with certain types of brain tumors feel better and have more treatment options.

  Recruiting Phase 1/2 Ann & Robert H Lurie Children's Hospital of Chicago · Washington D.C., District of Columbia and 2 other locations · NCT06712875

• Monitoring low-grade gliomas using blood samples

  This study is testing if analyzing blood samples can help monitor patients with low-grade brain tumors for signs of recurrence better than current MRI methods.

  Recruiting University Hospital, Caen · Caen · NCT06610851

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.